Lymphoma Management Updates for 2021 - SPOC
This lecture will review some of the new drugs recently FDA approved for management of lymphoma such as CAR-T therapy for relapsed/refractory Mantle Cell Lymphoma or follicular lymphoma. For rel/ref DLBCL, polatuzumab vedotin in combination with bendamustine and rituximab as well as tafasitamab plus lenalidomide have been approved in recent years. We will review the data and outcomes.
These courses are intended for medical, radiation, and surgical oncologists, hematologists, advanced practice nurses, registered nurses, physician assistants, radiologic technologists, researchers, pharmacists, trainees, allied health personnel, and others who are interested in care for patients and survivors in North Carolina.
- Identify new indications for CAR-T therapy: rel/ref Mantle cell and follicular lymphoma
- Discuss mechanism of action of polatuzumab vedotin
- Recall long-term data for use of tafasitimab + lenalidomide in rel/ref DLBCL
Taking the Course
To continue, click the button Take Course.
If you do not see the button, please ensure that you are logged in. If you are logged in and still don't see the button, please contact us at email@example.com or (919) 445–1000.
Anne W. Beaven, MD
Associate Professor of Medicine
This Non-Credit Course does not have accreditation. It only offers general participation certificates.
- 1.00 Participation